全文获取类型
收费全文 | 1713篇 |
免费 | 176篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 45篇 |
妇产科学 | 18篇 |
基础医学 | 205篇 |
口腔科学 | 38篇 |
临床医学 | 129篇 |
内科学 | 370篇 |
皮肤病学 | 29篇 |
神经病学 | 103篇 |
特种医学 | 68篇 |
外科学 | 194篇 |
综合类 | 144篇 |
一般理论 | 2篇 |
预防医学 | 217篇 |
眼科学 | 59篇 |
药学 | 95篇 |
中国医学 | 13篇 |
肿瘤学 | 153篇 |
出版年
2023年 | 10篇 |
2022年 | 7篇 |
2021年 | 41篇 |
2020年 | 38篇 |
2019年 | 41篇 |
2018年 | 58篇 |
2017年 | 46篇 |
2016年 | 38篇 |
2015年 | 51篇 |
2014年 | 61篇 |
2013年 | 75篇 |
2012年 | 131篇 |
2011年 | 135篇 |
2010年 | 74篇 |
2009年 | 64篇 |
2008年 | 95篇 |
2007年 | 111篇 |
2006年 | 92篇 |
2005年 | 68篇 |
2004年 | 67篇 |
2003年 | 56篇 |
2002年 | 52篇 |
2001年 | 31篇 |
2000年 | 38篇 |
1999年 | 33篇 |
1998年 | 23篇 |
1997年 | 20篇 |
1996年 | 13篇 |
1995年 | 9篇 |
1994年 | 6篇 |
1993年 | 8篇 |
1992年 | 19篇 |
1991年 | 17篇 |
1990年 | 25篇 |
1989年 | 15篇 |
1988年 | 21篇 |
1987年 | 25篇 |
1986年 | 15篇 |
1985年 | 22篇 |
1984年 | 12篇 |
1983年 | 14篇 |
1981年 | 6篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1977年 | 6篇 |
1976年 | 14篇 |
1975年 | 8篇 |
1974年 | 12篇 |
1973年 | 7篇 |
1970年 | 7篇 |
排序方式: 共有1894条查询结果,搜索用时 15 毫秒
1.
Francesca Tinti Anna Paola Mitterhofer Ilaria Umbro Peter Nightingale Nicholas Inston Mohammed Ghallab James Ferguson Darius F. Mirza Simon Ball Graham Lipkin Paolo Muiesan M. Thamara P. R. Perera 《Transplant international》2019,32(9):918-932
Patient selection for combined liver–kidney transplantation (CLKT) is a current issue on the background of organ shortage. This study aimed to compare outcomes and post‐transplant renal function for patients receiving CLKT and liver transplantation alone (LTA) based on native renal function using estimated glomerular filtration rate (eGFR) stratification. Using the UK National transplant database (NHSBT) 6035 patients receiving a LTA (N = 5912; 98%) or CLKT (N = 123; 2%) [2001–2013] were analysed, and stratified by KDIGO stages of eGFR at transplant (eGFR group‐strata). There was no difference in patient/graft survival between LTA and CLKT in eGFR group‐strata (P > 0.05). Of 377 patients undergoing renal replacement therapy (RRT) at time of transplantation, 305 (81%) and 72 (19%) patients received LTA and CLKT respectively. A significantly greater proportion of CLKT patients had severe end‐stage renal disease (eGFR < 30 ml/min/1.73 m2) at 1 year post‐transplant compared to LTA (9.5% vs. 5.7%, P = 0.001). Patient and graft survival benefit for patients on RRT at transplantation was favouring CLKT versus LTA (P = 0.038 and P = 0.018, respectively) but the renal function of the long‐term survivors was not superior following CLKT. The data does not support CLKT approach based on eGFR alone, and the advantage of CLKT appear to benefit only those who are on established RRT at the time of transplant. 相似文献
2.
Ashley Sharp Berit Muller-Pebody Andre Charlett Bharat Patel Rebecca Gorton Jonathan Lambourne Martina Cummins Adela Alcolea-Medina Mark Wilks Robin Smith Damien Mack Susan Hopkins Andrew Dodgson Phillipa Burns Nelun Perera Felicia Lim Gopal Rao Priya Khanna Elizabeth Johnson Andrew Borman Silke Schelenz Rebecca Guy Joanna Conneely Rohini J Manuel Colin S Brown 《Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin》2021,26(8)
Background Candida auris is an emerging multidrug-resistant fungal pathogen associated with bloodstream, wound and other infections, especially in critically ill patients. C. auris carriage is persistent and is difficult to eradicate from the hospital environment.AimWe aimed to pilot admission screening for C. auris in intensive care units (ICUs) in England to estimate prevalence in the ICU population and to inform public health guidance.MethodsBetween May 2017 and April 2018, we screened admissions to eight adult ICUs in hospitals with no previous cases of C. auris, in three major cities. Swabs were taken from the nose, throat, axilla, groin, perineum, rectum and catheter urine, then cultured and identified using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS). Patient records were linked to routine ICU data to describe and compare the demographic and health indicators of the screened cohort with a national cohort of ICU patients admitted between 2016 and 2017.ResultsAll C. auris screens for 921 adults from 998 admissions were negative. The upper confidence limit of the pooled prevalence across all sites was 0.4%. Comparison of the screened cohort with the national cohort showed it was broadly similar to the national cohort with respect to demographics and co-morbidities.ConclusionThese findings imply that C. auris colonisation among patients admitted to ICUs in England is currently rare. We would not currently recommend widespread screening for C. auris in ICUs in England. Hospitals should continue to screen high-risk individuals based on local risk assessment. 相似文献
3.
4.
5.
Warren Fiskus Christopher P. Mill Behnam Nabet Dimuthu Perera Christine Birdwell Taghi Manshouri Bernardo Lara Tapan M. Kadia Courtney DiNardo Koichi Takahashi Naval Daver Prithviraj Bose Lucia Masarova Naveen Pemmaraju Steven Kornblau Gautam Borthakur Guillermo Montalban-Bravo Guillermo Garcia Manero Sunil Sharma Matthew Stubbs Xiaoping Su Michael R. Green Cristian Coarfa Srdan Verstovsek Joseph D. Khoury Christopher R. Vakoc Kapil N. Bhalla 《Blood cancer journal》2021,11(5)
There is an unmet need to overcome nongenetic therapy-resistance to improve outcomes in AML, especially post-myeloproliferative neoplasm (MPN) secondary (s) AML. Studies presented describe effects of genetic knockout, degradation or small molecule targeted-inhibition of GFI1/LSD1 on active enhancers, altering gene-expressions and inducing differentiation and lethality in AML and (MPN) sAML cells. A protein domain-focused CRISPR screen in LSD1 (KDM1A) inhibitor (i) treated AML cells, identified BRD4, MOZ, HDAC3 and DOT1L among the codependencies. Our findings demonstrate that co-targeting LSD1 and one of these co-dependencies exerted synergistic in vitro lethality in AML and post-MPN sAML cells. Co-treatment with LSD1i and the JAKi ruxolitinib was also synergistically lethal against post-MPN sAML cells. LSD1i pre-treatment induced GFI1, PU.1 and CEBPα but depleted c-Myc, overcoming nongenetic resistance to ruxolitinib, or to BETi in post-MPN sAML cells. Co-treatment with LSD1i and BETi or ruxolitinib exerted superior in vivo efficacy against post-MPN sAML cells. These findings highlight LSD1i-based combinations that merit testing for clinical efficacy, especially to overcome nongenetic therapy-resistance in AML and post-MPN sAML.Subject terms: Acute myeloid leukaemia, Targeted therapies 相似文献
6.
7.
8.
9.
Perera Nandika Wijithalal Ruvini Galhena Gayani Ranawaka Gaya 《International journal of legal medicine》2022,136(2):415-422
International Journal of Legal Medicine - This study investigated genetic linkage, recombination fractions and mutation rates of 16 X chromosomal short tandem repeat (X-STR) markers using a... 相似文献
10.